United Capital Financial Advisors LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,108 shares of the medical research company’s stock, valued at approximately $1,567,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Financial Freedom LLC acquired a new stake in shares of IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the first quarter worth $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA during the fourth quarter worth $27,000. Compass Financial Management LLC bought a new stake in shares of IQVIA in the 2nd quarter valued at $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in IQVIA during the 4th quarter worth $27,000. Institutional investors own 89.62% of the company’s stock.
IQVIA Trading Down 0.7%
NYSE IQV opened at $260.48 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $265.25. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock’s 50 day moving average price is $222.14 and its two-hundred day moving average price is $189.62. The stock has a market capitalization of $42.88 billion, a price-to-earnings ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18.
IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.
Insider Buying and Selling at IQVIA
In related news, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 12,913 shares of company stock valued at $3,098,793. Corporate insiders own 1.70% of the company’s stock.
Wall Street Analyst Weigh In
IQV has been the subject of several recent analyst reports. Stifel Nicolaus increased their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. BMO Capital Markets raised their target price on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $241.88.
View Our Latest Stock Report on IQVIA
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
- Five stocks we like better than IQVIA
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
